ArticleNPJ microgravity2026
Infectious disease outcomes of NASA's health stabilization program.
Article in NPJ microgravity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To prevent pre-flight and on-orbit infections, NASA crew participate in a comprehensive Health Stabilization Program (HSP), which includes pre-flight quarantine, vaccination and demonstrated immunity, personal protective equipment, and crew and support personnel training. We aggregated historical spaceflight data to assess the incidence of pre-flight infectious exposures in spaceflight, to determine the effectiveness of HSP protocols, and to characterize risk factors associated with pre-flight exposure resulting in on-orbit illness. Medical and operational records on U.S. spaceflight missions from the Apollo Program through 2024 were retrospectively aggregated and analyzed. HSP-related mission-events were defined as an event where an identified failure, breach of protocol, or exposure occurred during the HSP/quarantine period resulting in one or more crewmember illnesses. In 196 aggregated spaceflight missions, 30 missions (15%) included infectious events among crew in the launch timeframe. In two missions (1%), launch of an ill crew further exposed additional on-orbit crews with infectious sequelae. Overall, launch delay due to crew infection occurred in two missions (1% of the aggregate cohort). While infectious events have occurred in spaceflight crew, HSP has resulted in overall mission success, with no HSP-related medical evacuations, no severe on-orbit medical sequelae, and no long-term health impacts related to HSP events.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.